The Eye Cancer That Finally Got a Real Drug
IDEAYA Biosciences just dropped uveal melanoma trial data that more than doubled progression-free survival in patients who had almost no treatment options. Wall Street loved it, an FDA filing is coming, and a half-billion-dollar partnership is fueling what comes next.
Imagine being diagnosed with a rare cancer, and your doctor tells you there's basically one approved drug. But it only works if you have the right genetic marker. And roughly half of patients don't.
That's been the reality for people with metastatic uveal melanoma, a cancer that starts in the eye and spreads (usually to the liver) with devastating speed. Two-year survival after metastasis sits around 25%. For patients who lack a specific immune marker called HLA-A*02:01, the medicine cabinet has been almost completely bare.
Until now.
A Trial That Actually Delivered
On April 13, IDEAYA Biosciences and its partner Servier dropped results from the Phase 2/3 OptimUM-02 trial, and the numbers were striking. The study tested a combination of darovasertib (a protein kinase C inhibitor, which blocks a key signaling protein that fuels tumor growth) plus crizotinib (Pfizer's Xalkori, a drug already approved for certain lung cancers) in first-line metastatic uveal melanoma patients who are HLA-A*02:01-negative.
The trial randomized 313 patients: 210 got the combo, and 103 received investigator's choice therapy (typically the immunotherapy cocktail of nivolumab plus ipilimumab). The primary endpoint was progression-free survival (PFS), meaning how long patients lived without their cancer getting worse.
The combo arm hit 6.9 months of median PFS. The control arm? Just 3.1 months. That's more than double, with a hazard ratio of 0.42 and a p-value below 0.0001. In clinical trial language, that's about as clean a win as you'll see.
Tumors Actually Shrank
PFS is important, but oncologists really perk up when tumors physically shrink. And here, the response rate told a compelling story.
37.1% of patients on the darovasertib combo saw their tumors shrink meaningfully by independent review, including five complete responses (meaning the cancer became undetectable on scans). Compare that to just 5.8% in the control arm. That's more than a sixfold difference.
To put this in perspective: the only currently approved drug for metastatic uveal melanoma, tebentafusp (brand name Kimmtrak, made by Immunocore), was approved in 2022. It extends survival, which is genuinely important. But its tumor shrinkage rate by standard imaging criteria ranges from roughly 0% to 9%. Tebentafusp works through a different mechanism; it improves overall survival without making tumors visibly smaller, which is unusual. But for patients watching their scans, a 37% response rate feels like a different universe.
More from this issue
View full issue →
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
